Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-501 T Cell Infusion for Hematologic Malignancies Post-Transplant
NCT02786485Phase 1Withdrawn
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- May 2016
- Primary completion
- Dec 2018
- Modality
- Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of rivogenlecleucel in leukemia, myelodysplastic syndrome (MDS), lymphoma and 1 more, sponsored by Bellicum Pharmaceuticals, Inc. Primary endpoint: Adverse events at 30 days. Planned start May 2016; status: withdrawn.
02
Drugs
rivogenlecleucel
03
Conditions
leukemiamyelodysplastic syndrome (MDS)lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT02786485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02786485.